1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

Code Break: Medicare Accelerates ‘J-Code’ Assignment To Boost Uptake Of New Drugs

 
• By Cathy Kelly

Manufacturers can apply for permanent Medicare reimbursement codes on a quarterly basis rather than annually going forward to allow for more frequent coding awards. Recently about two dozen drugs, including three biosimilars, received permanent codes earlier than usual.

Binary Code
CMS Concession On Coding A Welcome Change

Manufacturers of new drugs covered by Medicare Part B can obtain permanent, unique reimbursement codes months earlier than in the past under a new policy implemented by the US Centers for Medicare and Medicaid Services to make it easier for providers to adopt innovative treatments.

CMS is moving to a process that allows manufacturers to apply for permanent “J-codes" under the Healthcare Common Procedures Coding System (HCPCS) on a quarterly basis and receive codes more...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan

 
• By Lauren Flynn Kelly

Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

More from Government Payers

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By Cathy Kelly

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.